237 related articles for article (PubMed ID: 37935338)
1. The amyloid-β peptide: Guilty as charged?
Murphy MP; Buzinova VA; Johnson CE
Biochim Biophys Acta Mol Basis Dis; 2024 Feb; 1870(2):166945. PubMed ID: 37935338
[TBL] [Abstract][Full Text] [Related]
2. Exploring the Potential of Therapeutic Agents Targeted towards Mitigating the Events Associated with Amyloid-β Cascade in Alzheimer's Disease.
Behl T; Kaur I; Fratila O; Brata R; Bungau S
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33050199
[TBL] [Abstract][Full Text] [Related]
3. Alzheimer's disease.
De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
[TBL] [Abstract][Full Text] [Related]
4. Passive Immunotherapies Targeting Amyloid-
Marković M; Milošević J; Wang W; Cao Y
Mol Pharmacol; 2023 Dec; 105(1):1-13. PubMed ID: 37907353
[TBL] [Abstract][Full Text] [Related]
5. Role of monomeric amyloid-β in cognitive performance in Alzheimer's disease: Insights from clinical trials with secretase inhibitors and monoclonal antibodies.
Imbimbo BP; Ippati S; Watling M; Imbimbo C
Pharmacol Res; 2023 Jan; 187():106631. PubMed ID: 36586644
[TBL] [Abstract][Full Text] [Related]
6. The Y
Matrone C; Iannuzzi F; Annunziato L
Ageing Res Rev; 2019 Jul; 52():120-128. PubMed ID: 31039414
[TBL] [Abstract][Full Text] [Related]
7. Progress toward Alzheimer's disease treatment: Leveraging the Achilles' heel of Aβ oligomers?
Fantini J; Chahinian H; Yahi N
Protein Sci; 2020 Aug; 29(8):1748-1759. PubMed ID: 32567070
[TBL] [Abstract][Full Text] [Related]
8. Critical Appraisal of Amyloid Lowering Agents in AD.
Decourt B; Boumelhem F; Pope ED; Shi J; Mari Z; Sabbagh MN
Curr Neurol Neurosci Rep; 2021 Jun; 21(8):39. PubMed ID: 34110536
[TBL] [Abstract][Full Text] [Related]
9. Development of amyloid beta-directed antibodies against Alzheimer's disease: Twists and turns.
Lu D; Dou F; Gao J
Drug Discov Ther; 2023; 17(6):440-444. PubMed ID: 38220210
[TBL] [Abstract][Full Text] [Related]
10. Anti-Amyloid Therapies for Alzheimer's Disease and the Amyloid Cascade Hypothesis.
Fedele E
Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37833948
[TBL] [Abstract][Full Text] [Related]
11. Revisiting the Amyloid Cascade Hypothesis: From Anti-Aβ Therapeutics to Auspicious New Ways for Alzheimer's Disease.
Uddin MS; Kabir MT; Rahman MS; Behl T; Jeandet P; Ashraf GM; Najda A; Bin-Jumah MN; El-Seedi HR; Abdel-Daim MM
Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32824102
[TBL] [Abstract][Full Text] [Related]
12. Immunization targeting a minor plaque constituent clears β-amyloid and rescues behavioral deficits in an Alzheimer's disease mouse model.
Morales-Corraliza J; Schmidt SD; Mazzella MJ; Berger JD; Wilson DA; Wesson DW; Jucker M; Levy E; Nixon RA; Mathews PM
Neurobiol Aging; 2013 Jan; 34(1):137-45. PubMed ID: 22608241
[TBL] [Abstract][Full Text] [Related]
13. Anti-PrPC monoclonal antibody infusion as a novel treatment for cognitive deficits in an Alzheimer's disease model mouse.
Chung E; Ji Y; Sun Y; Kascsak RJ; Kascsak RB; Mehta PD; Strittmatter SM; Wisniewski T
BMC Neurosci; 2010 Oct; 11():130. PubMed ID: 20946660
[TBL] [Abstract][Full Text] [Related]
14. Fibrillar Aβ triggers microglial proteome alterations and dysfunction in Alzheimer mouse models.
Sebastian Monasor L; Müller SA; Colombo AV; Tanrioever G; König J; Roth S; Liesz A; Berghofer A; Piechotta A; Prestel M; Saito T; Saido TC; Herms J; Willem M; Haass C; Lichtenthaler SF; Tahirovic S
Elife; 2020 Jun; 9():. PubMed ID: 32510331
[TBL] [Abstract][Full Text] [Related]
15. Aducanumab, gantenerumab, BAN2401, and ALZ-801-the first wave of amyloid-targeting drugs for Alzheimer's disease with potential for near term approval.
Tolar M; Abushakra S; Hey JA; Porsteinsson A; Sabbagh M
Alzheimers Res Ther; 2020 Aug; 12(1):95. PubMed ID: 32787971
[TBL] [Abstract][Full Text] [Related]
16. Anti-Amyloid Immunotherapies for Alzheimer's Disease: A 2023 Clinical Update.
Yadollahikhales G; Rojas JC
Neurotherapeutics; 2023 Jul; 20(4):914-931. PubMed ID: 37490245
[TBL] [Abstract][Full Text] [Related]
17. Biomarkers in amyloid-β immunotherapy trials in Alzheimer's disease.
Blennow K; Hampel H; Zetterberg H
Neuropsychopharmacology; 2014 Jan; 39(1):189-201. PubMed ID: 23799530
[TBL] [Abstract][Full Text] [Related]
18. Systemic vaccination with anti-oligomeric monoclonal antibodies improves cognitive function by reducing Aβ deposition and tau pathology in 3xTg-AD mice.
Rasool S; Martinez-Coria H; Wu JW; LaFerla F; Glabe CG
J Neurochem; 2013 Aug; 126(4):473-82. PubMed ID: 23672786
[TBL] [Abstract][Full Text] [Related]
19. Key Peptides and Proteins in Alzheimer's Disease.
Penke B; Bogár F; Paragi G; Gera J; Fülöp L
Curr Protein Pept Sci; 2019; 20(6):577-599. PubMed ID: 30605056
[TBL] [Abstract][Full Text] [Related]
20. Selective neutralization of APP-C99 with monoclonal antibodies reduces the production of Alzheimer's Aβ peptides.
Houacine J; Bolmont T; Aeschbach L; Oulad-Abdelghani M; Fraering PC
Neurobiol Aging; 2012 Nov; 33(11):2704-14. PubMed ID: 22317957
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
